Abcellera Biologics/ABCL

$3.76

0.53%
-
1D1W1MYTD1YMAX

About Abcellera Biologics

AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.

Ticker

ABCL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Carl Hansen

Employees

586

Headquarters

Vancouver, Canada

ABCL Metrics

BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$0.51
EPS
0.41
Beta
-
Dividend rate
$1.1B
0.41117
$8.05
$3.62
1.4M
7.761
7.754
-9.92%
-12.56%
-10.62%
29.908
0.946
1.111
-80.23%
-175.79%
-45.36%

What the Analysts think about ABCL

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
305.59% upside
High $28.00
Low $7.00
$3.76
Current price
$15.25
Average price target

ABCL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-410.1% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.9M
8.79%
Net income
-$41M
-13.8%
Profit margin
-410.1%
-20.77%

ABCL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.79%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.11
-$0.10
-$0.17
-$0.14
-
Expected
-$0.13
-$0.13
-$0.13
-$0.17
-$0.14
Surprise
-15.38%
-25.62%
28.57%
-15.79%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Abcellera Biologics stock?

Abcellera Biologics (ABCL) has a market cap of $1.1B as of May 22, 2024.

What is the P/E ratio for Abcellera Biologics stock?

The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of May 22, 2024.

Does Abcellera Biologics stock pay dividends?

No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Abcellera Biologics dividend payment date?

Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.

What is the beta indicator for Abcellera Biologics?

Abcellera Biologics (ABCL) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Abcellera Biologics stock price target?

The target price for Abcellera Biologics (ABCL) stock is $15.25, which is 296.1% above the current price of $3.85. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Abcellera Biologics stock

Buy or sell Abcellera Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing